ClearPoint Neuro Reports Third Quarter 2026 Results
ClearPoint Neuro reported Q3 2026 revenue of $12.1 million, up 36% year-over-year, boosted by the IRRAflow portfolio acquired with IRRAS in late 2025. Neurosurgery navigation and therapy revenue grew 59% to $5.4 million and capital equipment/software hit a record $1.7 million, while biologics and drug delivery returned to double-digit growth at $4.9 million. Profitability remains the weak spot: gross margin fell to 58% from 63%, operating loss widened to $6.3 million, and net loss was $7.5 million ($0.24 per share) as operating expenses grew 23%.
Key figures
- Revenue
- 12075000
- Guidance
- FY2026 revenue $48.0 million-$50.0 million
- Revenue Yoy
- 36%
- Gross margin
- 58%
- Opex growth yoy
- 23%
- Atm net proceeds
- 22000000
- Operating expenses
- 13400000
- Cash and equivalents
- 46200000
- Biologics drug delivery revenue
- 4900000
- Neurosurgery navigation revenue
- 5400000
- Capital equipment software revenue
- 1700000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.